Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTNVFZ)

Drug Name

4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Drug Info

Synonyms

252722-52-4; 4-(Piperazin-1-yl)-1H-pyrrolo[2,3-d]pyrimidine; 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine; 4-(1-Piperazinyl)-1H-pyrrolo[2,3-d]pyrimidine; CHEMBL595554; 1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperazine; 6J9; SCHEMBL2251760; DTXSID20592472; MolPort-028-913-269; BDBM50304819; AKOS022175220; AKOS016374229; MCULE-3871238079; ACM252722524; NS-02114; DB-067363; AX8159612; KB-186079; AJ-103002

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 18008465
CAS Number: CAS 252722-52-4
TTD Drug ID: DMTNVFZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 2C receptor (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[3]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[4]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[5]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[6]
Methysergide	DM1EF73	Migraine	8A80	Approved	[7]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[8]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[9]
SR46349B	DM1ODMR	Primary insomnia	7A00	Phase 3	[10]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
2	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
3	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
4	The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
5	Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
6	Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
7	Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
8	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
9	Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
10	SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
11	Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.